By Gavin Gibbon
Pfizer and BioNTech working on mRNA-based vaccine programme, BNT162
Scientists are helping develop a potential vaccine aimed at preventing the coronavirus infection.
Pfizer Inc and BioNTech have signed a deal to work together on the mRNA-based vaccine programme, BNT162, which is expected to enter clinical testing by the end of April.
Sinan Atlig, regional president for Pfizer Biopharma in Africa and the Middle East, told Arabian Business: “Addressing this disease is a challenge as there is still much unknown about the exact source of the outbreak and the complexity of emerging viruses that changes daily.
“A challenge like coronavirus requires every organization to bring forward its resources and expertise to manage health risks that evolve daily. Ultimately, each of us have been called to contribute to the global efforts and our scientists have been quick to share their expertise with others.”
To date the number of novel coronavirus cases globally stood at 308,130 with 13,444 deaths, across 170 countries and territories.
Multiple research and development sites from both companies will be used, including in the United States and Germany, to house the activities identified by the collaboration agreement.
Atlig added: “We continue to have discussions with leading global health, regulatory and policymakers from our healthcare innovation ecosystem as to how we can collaborate and address this urgent public health threat.
“Given the severity of the situation and how quickly Covid-19 has moved around the world, we are still working through the details, and we are committed to providing patients globally, access to high-quality medicines and vaccines.”
Earlier this month Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat Covid-19.